Our blog
Into 2019 - Thoughts for the New Year
Heather Graz

With the holiday season winding down, it is time to pick up where 2018’s business activities left off. Going into the new year always brings with it both a chance to reflect on the outcomes of the past 12 months and opportunity to start realising the planned and emergent business opportunities for the upcoming 12 months.

2018 saw highlights across several areas at Neem Biotech. Existing networks were strengthened and new relationships developed that gave opportunity to extend our reach and impact in the field of antimicrobial resistance (AMR). We were awarded grant funding in excess of £600 000. Together these successes culminated in exciting, robust and potentially ground-breaking science being produced in our laboratories.

Changes in FDA antibiotic classification created a favourable environment that looks set to accelerate the progress of our candidate compounds towards the clinic. Emerging global antibiotic market access discussions allowed us to take an active role in the increasingly unified UK- and European-wide  AMR industry voice calling for a bespoke and fit-for-purpose antimicrobial drug development model to help avert the imminent global AMR crisis. A particular highlight in this regard was the pioneering work that we were able to carry out together with the BIA and AMR Centre.

As we look forward to the next 12 months at Neem Biotech, we have the target of doing that which we do best - translating aspirational antimicrobial solutions into reality in wound and respiratory infections - firmly set in our sights to make sure that we play our part in curtailing the spread of AMR.

With that in mind, Neem Biotech’s wish for the AMR-focused biotech and pharma industry would be a year of strong science R&D and creation of a concrete and bespoke business model for development of antimicrobial interventions in 2019.

We would love to hear what a successful 2019 would look like from your standpoint.

Comments

No comments available

Note: All comments will be moderated before being published.
The value of antibiotics
Heather Graz

It is increasingly widely accepted that, in the evolving world of healthcare and health economics, a way of demonstrating value is essential. Exactly how this concept of value should be defined and, on a more practical note, how it can best be quantified, remains to be agreed.  

This lack of consensus has significance across all avenues of drug development. It has even more significant implications, though, for the development of new antimicrobial measures, where a particularly stark tension exists between supply- and demand-related factors.

Scenarios, for example, where it is cheaper to buy antibiotics than to pay for clean water reflect this disparity at a practical level. They highlight the need for workable solutions to be found that address both the scientific and the economic aspects of developing and delivering new and improved antimicrobial interventions.

Much is being done at a grassroots level to meet this challenge head on. Recommendations from the recent O’Neill reports highlight a broad range of intervention avenues for both industry and public healthcare players to adopt. These cross disciplines and include scientific, policy and financial recommendations. The need to revisit reimbursement and funding options for developers of new solutions is recognised amongst these. More discussion than action has however taken place around this hurdle. At the heart of this situation lies the need for a satisfactory way to be developed to allow us to quantify the communal and individual value of antimicrobial interventions.

Ultimately, the challenge of managing antimicrobials in modern society may well depend in large part on how the economics of the situation are handled. Some commentators have said that what is needed is a workable reimbursement programme that is accepted globally. Is this realistic or too big an ask and how do we align and combine subjective and objective components of the concept of value into a tool with universal applicability? Time will tell. In the meantime, feel free to join the conversation about what value looks like in the development of novel antimicrobial interventions.

Comments

No comments available

Note: All comments will be moderated before being published.

Our blog
Into 2019 - Thoughts for the New Year
Heather Graz

With the holiday season winding down, it is time to pick up where 2018’s business activities left off. Going into the new year always brings with it both a chance to reflect on the outcomes of the past 12 months and opportunity to start realising the planned and emergent business opportunities for the upcoming 12 months.

2018 saw highlights across several areas at Neem Biotech. Existing networks were strengthened and new relationships developed that gave opportunity to extend our reach and impact in the field of antimicrobial resistance (AMR). We were awarded grant funding in excess of £600 000. Together these successes culminated in exciting, robust and potentially ground-breaking science being produced in our laboratories.

Changes in FDA antibiotic classification created a favourable environment that looks set to accelerate the progress of our candidate compounds towards the clinic. Emerging global antibiotic market access discussions allowed us to take an active role in the increasingly unified UK- and European-wide  AMR industry voice calling for a bespoke and fit-for-purpose antimicrobial drug development model to help avert the imminent global AMR crisis. A particular highlight in this regard was the pioneering work that we were able to carry out together with the BIA and AMR Centre.

As we look forward to the next 12 months at Neem Biotech, we have the target of doing that which we do best - translating aspirational antimicrobial solutions into reality in wound and respiratory infections - firmly set in our sights to make sure that we play our part in curtailing the spread of AMR.

With that in mind, Neem Biotech’s wish for the AMR-focused biotech and pharma industry would be a year of strong science R&D and creation of a concrete and bespoke business model for development of antimicrobial interventions in 2019.

We would love to hear what a successful 2019 would look like from your standpoint.


Comments

No comments available

Note: All comments will be moderated before being published.
The value of antibiotics
Heather Graz

It is increasingly widely accepted that, in the evolving world of healthcare and health economics, a way of demonstrating value is essential. Exactly how this concept of value should be defined and, on a more practical note, how it can best be quantified, remains to be agreed.  

This lack of consensus has significance across all avenues of drug development. It has even more significant implications, though, for the development of new antimicrobial measures, where a particularly stark tension exists between supply- and demand-related factors.

Scenarios, for example, where it is cheaper to buy antibiotics than to pay for clean water reflect this disparity at a practical level. They highlight the need for workable solutions to be found that address both the scientific and the economic aspects of developing and delivering new and improved antimicrobial interventions.

Much is being done at a grassroots level to meet this challenge head on. Recommendations from the recent O’Neill reports highlight a broad range of intervention avenues for both industry and public healthcare players to adopt. These cross disciplines and include scientific, policy and financial recommendations. The need to revisit reimbursement and funding options for developers of new solutions is recognised amongst these. More discussion than action has however taken place around this hurdle. At the heart of this situation lies the need for a satisfactory way to be developed to allow us to quantify the communal and individual value of antimicrobial interventions.

Ultimately, the challenge of managing antimicrobials in modern society may well depend in large part on how the economics of the situation are handled. Some commentators have said that what is needed is a workable reimbursement programme that is accepted globally. Is this realistic or too big an ask and how do we align and combine subjective and objective components of the concept of value into a tool with universal applicability? Time will tell. In the meantime, feel free to join the conversation about what value looks like in the development of novel antimicrobial interventions.


Comments

No comments available

Note: All comments will be moderated before being published.